Literature DB >> 19952058

Why mortality is increased in health-care-associated pneumonia: lessons from pneumococcal bacteremic pneumonia.

Jordi Rello1, Manel Luján, Miguel Gallego, Jordi Vallés, Yolanda Belmonte, Dionisia Fontanals, Emili Diaz, Thiago Lisboa.   

Abstract

BACKGROUND: A cohort of patients with bacteremic Streptococcus pneumoniae pneumonia was reviewed to assess why mortality is higher in health-care-associated pneumonia (HCAP) than in community-acquired pneumonia (CAP).
METHODS: A prospective cohort of all adult patients with bacteremic pneumococcal pneumonia attended at the ED was used.
RESULTS: One hundred eighty-four cases were classified as CAP and 44 (19%) as HCAP. Fifty-two (23%) were admitted to the ICU. Three (1.5%) isolates were resistant to beta-lactams, and only two patients received inappropriate therapy. The CAP cohort was significantly younger (median age 68 years, interquartile range [IQR] 42-78 vs 77 years, IQR 67-82, P < .001). The HCAP cohort presented a higher Charlson index (2.81 +/- 1.9 vs 1.23 +/- 1.42, P < .001) and had higher severity of illness at admission (altered mental status, respiratory rate > 30/min, Pao(2)/Fio(2) < 250, and multilobar involvement). HCAP patients had a lower rate of ICU admission (11.3% vs 25.5%, P < .05), and a trend toward lower mechanical ventilation (9% vs 19%, P = .17) and vasopressor use (9% vs 18.4%, P = .17) were documented. More patients in the HCAP cohort presented with a pneumonia severity index score > 90 (class IV-V, 95% vs 65%, P < .001), and 30-day mortality was significantly higher (29.5% vs 7.6%, P < .001). A multivariable regression logistic analysis adjusting for underlying conditions and variables related to severity of illness confirmed that HCAP is an independent variable associated with increased mortality (odds ratio = 5.56; 95% CI, 1.86-16.5).
CONCLUSIONS: Pneumococcal HCAP presents excess mortality, which is independent of bacterial susceptibility. Differences in outcomes were probably due to differences in age, comorbidities, and criteria for ICU admission rather than to therapeutic decisions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952058     DOI: 10.1378/chest.09-2175

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

1.  Molecular epidemiological characteristics of Klebsiella pneumoniae associated with bacteremia among patients with pneumonia.

Authors:  Ryota Ito; Yuichiro Shindo; Daisuke Kobayashi; Masahiko Ando; Wanchun Jin; Jun-ichi Wachino; Keiko Yamada; Kouji Kimura; Tetsuya Yagi; Yoshinori Hasegawa; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2015-01-07       Impact factor: 5.948

Review 2.  Elderly patients with community-acquired pneumonia: optimal treatment strategies.

Authors:  Ulrich Thiem; Hans-Jürgen Heppner; Ludger Pientka
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

3.  Understanding the Concept of Health Care-Associated Pneumonia in Lung Transplant Recipients.

Authors:  Federico Palacio; Luis F Reyes; Deborah J Levine; Juan F Sanchez; Luis F Angel; Juan F Fernandez; Stephanie M Levine; Jordi Rello; Ali Abedi; Marcos I Restrepo
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

4.  Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study.

Authors:  Marco Falcone; Salvatore Corrao; Giuseppe Licata; Pietro Serra; Mario Venditti
Journal:  Intern Emerg Med       Date:  2012-06-12       Impact factor: 3.397

5.  One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System.

Authors:  Joe L Hsu; Andrew M Siroka; Mark W Smith; Mark Holodniy; G Umberto Meduri
Journal:  Int J Infect Dis       Date:  2011-03-09       Impact factor: 3.623

6.  Comparison of severe healthcare-associated pneumonia with severe community-acquired pneumonia.

Authors:  Byeong-Ho Jeong; Eun Ju Jeon; Hongseok Yoo; Won-Jung Koh; Gee Young Suh; Man Pyo Chung; O Jung Kwon; Kyeongman Jeon
Journal:  Lung       Date:  2013-12-01       Impact factor: 2.584

Review 7.  Vaccines for preventing pneumococcal infection in adults.

Authors:  Sarah Moberley; John Holden; David Paul Tatham; Ross M Andrews
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

8.  Etiology and Prognosis of Pneumonia in Patients with Solid Tumors: A Prospective Cohort of Hospitalized Cases.

Authors:  Ana Fernández-Cruz; Laura Ortega; Gonzalo García; Iria Gallego; Ana Álvarez-Uría; Esther Chamorro-de-Vega; José Javier García-López; Ricardo González-Del-Val; Pablo Martín-Rabadán; Carmen Rodríguez; María Luisa Pedro-Botet; Miguel Martín; Emilio Bouza
Journal:  Oncologist       Date:  2020-02-11

Review 9.  Guideline-concordant antimicrobial therapy for healthcare-associated pneumonia: a systematic review and meta-analysis.

Authors:  Anthony X Troitino; Jahan Porhomayon; Ali A El-Solh
Journal:  Lung       Date:  2013-04-10       Impact factor: 2.584

10.  Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study.

Authors:  Teresa Cardoso; Orquídea Ribeiro; Irene César Aragão; Altamiro Costa-Pereira; António Eugénio Sarmento
Journal:  BMC Infect Dis       Date:  2012-12-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.